2016
DOI: 10.2146/ajhp150163
|View full text |Cite
|
Sign up to set email alerts
|

New combination antiviral for the treatment of hepatitis C

Abstract: Viekira, the first coformulated direct-acting antiviral that targets different stages of the HCV life cycle, is an interferon-free treatment for HCV genotype 1 infection. It is associated with a virological cure rate of ≥90% and treatment durations of 12 and 24 weeks. Viekira is also effective and safe for patients who have undergone liver transplantation, are coinfected with HIV, or have advanced kidney disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 37 publications
0
6
0
Order By: Relevance
“…(52) Additionally, Lam, J T. & Salazar, L. (2016) reported the effects of hepatitis C on families, work environments, and on society as a whole, are remarkable. (53) An important new finding was that self-management program participants experienced changes in generic quality of life often emerge more slowly as short-term improvements in disease-related knowledge and selfefficacy for managing one's chronic disease are practiced consistently over a longer period of time (Bandura, 2001). (54) Over the past three years, an exciting combination of tools, ideas and networks have grasped.…”
Section: Discussionmentioning
confidence: 99%
“…(52) Additionally, Lam, J T. & Salazar, L. (2016) reported the effects of hepatitis C on families, work environments, and on society as a whole, are remarkable. (53) An important new finding was that self-management program participants experienced changes in generic quality of life often emerge more slowly as short-term improvements in disease-related knowledge and selfefficacy for managing one's chronic disease are practiced consistently over a longer period of time (Bandura, 2001). (54) Over the past three years, an exciting combination of tools, ideas and networks have grasped.…”
Section: Discussionmentioning
confidence: 99%
“…Dasabuvir is an effective non-nucleoside inhibitor that targets the palm domain of hepatitis C virus (HCV) NS5B polymerase. , It was discovered and developed together with the NS5A inhibitor ombitasvir and NS3/4A protease inhibitor paritaprevir as an interferon-free direct-acting antiviral (DAA) combination therapy (Viekira Pak) for the treatment of genotype 1 chronic HCV infection, including in those patients with compensated cirrhosis. , Viekira Pak achieved a high sustained viral response 12 weeks after dosing (SVR12) with a considerably improved safety profile and represented a significant advancement compared to interferon-based regiment . The free acid of dasabuvir is a classic “Rule of 5” (Ro5) molecule, and its molecular structure is characterized by a uracil group and a sulfonamide group, two weakly acidic groups with p K a values of 8.2 and 9.2, respectively (Scheme ).…”
Section: Introductionmentioning
confidence: 99%
“…Two newly approved combination hepatitis C drugs (Zepatier: elbasvir + grazoprevir and Viekira and PaK: ombitasvir + paritaprevir + ritonavir + dasabuvir) have demonstrated improved safety and efficacy for treating genotype 1 or 4 HCV-infected persons [ 8 ]. Although these treatments offer renewed hope toward curing HCV infection, the issues of drug resistance, narrow genotype specificity, lack of vaccines, and high cost remain [ [9] , [10] , [11] , [12] ]. It is still imperative to develop new anti-HCV agents, especially those with novel mechanisms of action (MOAs) and new molecular structures.…”
Section: Introductionmentioning
confidence: 99%